Pemetrexed in the first line treatment in non-small cell lung cancer (NSCLC): A multicentre prospective analysis of data from clinical practise of Czech Republic
J. Skrickova, K. Hejduk, Z. Bortlicek, M. Pesek, V. Kolek, L. Koubkova, P. Zatloukal, F. Salajka, M. Zemanova, D. Sixtova, J. Roubec, H. Coupkova (Brno, Plzen, Olomouc, Praha, Hradec Kralove, Ostrava, Czech Republic)
Source: Annual Congress 2012 - Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Poster Discussion
Number: 2915
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Skrickova, K. Hejduk, Z. Bortlicek, M. Pesek, V. Kolek, L. Koubkova, P. Zatloukal, F. Salajka, M. Zemanova, D. Sixtova, J. Roubec, H. Coupkova (Brno, Plzen, Olomouc, Praha, Hradec Kralove, Ostrava, Czech Republic). Pemetrexed in the first line treatment in non-small cell lung cancer (NSCLC): A multicentre prospective analysis of data from clinical practise of Czech Republic. Eur Respir J 2012; 40: Suppl. 56, 2915
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: